We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for tafamidis and tafamidis meglumine (Pfizer Australia Pty Ltd)
Active ingredients
tafamidis and tafamidis meglumine
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Capsule, soft
Indication
For the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) due to wild type or variant transthyretin.